{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-131746","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.337449+00:00","generated_at":"2026-05-15T08:22:29.884508+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Annexon reports Q4 and FY2025 net loss of $48.3M and $208.5M; cash $238.3M; vonaprument Phase 3 data due Q4 2026","bullets":["Net loss Q4 2025 $48.3M ($0.28/sh) and FY2025 $208.5M ($1.34/sh); FY2024 net loss was $138.2M.","Cash, equivalents and short-term investments $238.3M at Dec 31, 2025; funds operations into H2 2027.","R&D expenses $184.7M for FY2025, up from $119.4M due to Phase 3 ARCHER II and regulatory filings.","Vonaprument Phase 3 ARCHER II topline data in geographic atrophy expected Q4 2026; enrollment completed July 2025.","Tanruprubart MAA filed in EU for GBS; U.S. BLA submission planned in 2026 based on FORWARD study."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-131746","json":"https://secwatch.observer/filing/0001193125-26-131746.json","markdown":"https://secwatch.observer/filing/0001193125-26-131746.md","text":"https://secwatch.observer/filing/0001193125-26-131746.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000119312526131746/0001193125-26-131746-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000119312526131746/annx-20260330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:22:29.884508+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"01061f7cace985a4bd08c6075ccfd668098fa25b","claim":"Annexon, Inc. reported financial results for the fourth quarter and the year ended December 31, 2025.","evidence_excerpt":"On March 30, 2026, Annexon, Inc. (the “Company”) announced certain financial results for the fourth quarter and the year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528115/000119312526131746/0001193125-26-131746-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and the year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}